What is Semax pharmacokinetics?: half-life, bioavailability and duration of action

Pharmacokinetics is the branch of science that investigates what happens to a substance in the body – how it is absorbed, where it goes, how it breaks down, and how long it remains active. With Semax, this picture is more complex than a simple measure of its time in the bloodstream.

Semax is a synthetic heptapeptide – an artificially produced chain of seven amino acids. Its structure was deliberately designed to be more resistant to degradation than the natural hormone fragment it was based on. A short, three-amino-acid tail, known as Pro-Gly-Pro, was added to the end of the molecule specifically to lengthen the peptide’s period of biological activity in the body.

To fully understand Semax's behaviour over time, researchers analysed its absorption, speed of brain penetration, breakdown mechanisms, activity of metabolic products, and the actual duration of its effects. Each of these elements contributes to a pharmacokinetic profile far more complex than a single half-life number would suggest.

It should be noted that almost all available pharmacokinetic data originates from animal studies – primarily in rats – using radioactively labelled versions of the peptide to track its journey through the body. Direct pharmacokinetic measurements in humans are very limited.

How is Semax absorbed and how quickly does it reach the brain?

Semax reaches the brain exceptionally quickly following intranasal administration. In studies on rats using a radioactively labelled version of the peptide, intranasal administration at a dose of 50 micrograms per kilogram of body weight allowed Semax to be detected in brain tissue after just 2 minutes [1]. Approximately 80% of the substance reaching the brain at this early stage was intact, native Semax, rather than its metabolic fragments [1]. This confirms that the parent molecule itself – and not merely its breakdown products – reaches the brain rapidly and in significant quantities.

This rapid access to the brain is possible because the nose provides a direct route to the brain via the olfactory pathway – the neural network responsible for the sense of smell. This pathway completely bypasses the bloodstream and the blood-brain barrier, allowing intranasally administered peptides to reach brain tissue much more effectively than through other routes of administration.

The speed of Semax's biological effects corresponds to its rapid brain penetration. Changes in the activity of neurotrophin genes – genes responsible for the production of proteins supporting the growth and survival of brain cells – were detectable in the hippocampus and frontal cortex of rats just 20 minutes after a single intranasal dose [2]. In healthy volunteers, brain imaging studies using resting-state functional MRI – a technique that measures brain activity through changes in blood flow – showed measurable changes in brain network activity as early as 5 and 20 minutes after intranasal administration of Semax [3]. This provides direct evidence from human studies that Semax engages the central nervous system within minutes of intranasal administration.

What is the half-life of Semax?

The half-life of Semax as an intact molecule in biological fluids is relatively short – as with most peptides – however, the total biological activity time extends significantly beyond this point. The half-life is the time after which half of the substance is broken down or removed from the body.

In laboratory studies analysing the breakdown of Semax in the presence of rat brain cell membrane material, the intact molecule exhibited a half-life exceeding one hour [4]. This is significantly longer than that of many natural brain signalling peptides, which can be degraded within seconds to minutes.

In the blood and serum of rats, researchers identified enzymes responsible for the breakdown of Semax. The main ones are aminopeptidases – particularly sensitive to a compound called bestatin – and an enzyme called angiotensin-converting enzyme (ACE). These enzymes are responsible for most of the Semax-degrading activity in the blood [5]. The process begins at the N-terminal end of the molecule – the beginning of the amino acid chain – where the first two amino acids, methionine and glutamic acid, are cleaved off first, forming intermediate fragments which remain biologically active themselves [5].

It is worth explicitly emphasising one key fact: no published pharmacokinetic studies in humans have established the exact value of Semax's plasma half-life in humans. Values provided in non-specialist online sources do not originate from peer-reviewed scientific research and should be approached with caution. What the published scientific literature confirms is that the intact molecule is relatively rapidly degraded in biological fluids, its main degradation products retain their own biological activity, and the total duration of Semax's pharmacological action is considerably longer than the elimination of the parent molecule alone would suggest.

How is Semax metabolised?

Semax is metabolised – broken down – primarily through a stepwise process where enzymes sequentially cleave amino acids from the N-terminal end of the chain. Importantly, this breakdown does not simply mean Semax is deactivated. Instead, a series of smaller fragments are produced, each of which retains its own biological activity.

The main metabolic pathway proceeds as follows: enzymes called dipeptidyl aminopeptidases and aminopeptidases first cleave two N-terminal amino acids – methionine and glutamate – from the Semax molecule. This creates the five-amino-acid fragment HFPGP (His-Phe-Pro-Gly-Pro), which is the main intermediate breakdown product. HFPGP is then further broken down into a three-amino-acid fragment PGP (Pro-Gly-Pro), which is the main end-metabolite [4], [6].

Studies using radioactively labelled Semax have confirmed that HFPGP and PGP are the main breakdown products. The pattern of metabolite formation differed slightly between glial cells – the supporting cells of the brain – and neurons, suggesting that different cell types process Semax slightly differently [6].

Comparative studies of the distribution in nasal tissue, brain microsomal fractions, and rat blood have shown that the C-terminal fragment of PGP – the tail of the molecule – is significantly more resistant to enzymatic degradation than the N-terminal fragment derived from ACTH. This means that enzymatic attacks mainly occur from the front of the molecule, while its posterior part remains relatively stable [7].

Researchers also examined modified versions of Semax to understand what makes it susceptible to metabolic breakdown. Replacing N-terminal methionine with alanine, glycine, or threonine yielded Semax analogues more resistant to enzyme action than the original [8]. Furthermore, a Semax version with a chemical modification known as acetylation at the N-terminal end – known as Ac-Semax – exhibited a changed breakdown pattern and different biological properties, although it did not improve cell protection against copper-induced toxicity [9].

The concept of synakton is essential for understanding why Semax metabolism is of pharmacological significance. The metabolic cascade from Semax to HFPGP to PGP does not represent simple inactivation – it generates a sequence of biologically active molecules. Each of these interacts with overlapping, yet distinct, binding sites on the surface of nerve cells [10]. Of all the breakdown fragments studied, HFPGP – the first and main breakdown product – demonstrated the strongest ability to compete for the same binding sites as the original Semax molecule [10]. This means that as Semax is cleared from the system, its first breakdown product effectively takes over its action, prolonging the overall duration of pharmacological effect.

What is the bioavailability of Semax via different routes of administration?

Bioavailability describes how much of a administered substance actually reaches its target in an active form. For Semax, the route of administration is of significant importance – not only for the amount reaching the brain, but also for the effects that are produced.

Nasal administration is both a clinically standard and a pharmacokinetically most effective method for delivering Semax to the brain. As described above, this route delivers Semax directly to the brain via the olfactory pathways, completely bypassing the bloodstream.

Direct pharmacokinetic comparisons between intranasal and subcutaneous administration in controlled studies are limited in the available literature. However, behavioural and pharmacodynamic studies – measuring actual effects rather than blood levels – provide indirect information. Studies comparing intraperitoneal injection with intranasal administration have shown that the intranasal route was more effective in improving learning in memory tasks, while intraperitoneal injection was required to induce analgesic effects that intranasal administration did not achieve [11].

This route-dependent difference in effects suggests that both methods yield different body distribution patterns. Intranasal administration promotes high concentrations in the brain, whereas injection provides broader systemic distribution, reaching peripheral tissues and receptors outside the brain as well [11]. The superior cognitive effects of intranasal Semax compared to injection are consistent with data on rapid brain penetration, confirming detectable levels in the brain within 2 minutes of intranasal administration [1].

When administered orally – by swallowing Semax – no published pharmacokinetic studies have investigated its absorption from the gastrointestinal tract. Given that peptides are generally rapidly degraded by digestive enzymes in the stomach and intestines before they can be absorbed, the bioavailability of intact Semax molecules following oral administration is likely negligible without specialised protective delivery systems. The C-terminal fragment of PGP may exhibit some ability to survive digestion due to the known stability of this class of peptides, however, this has not been directly confirmed in published studies [12].

How long do the effects of Semax last?

The duration of Semax's effects varies significantly depending on the measured effect. It ranges from a few hours for acute changes in neurotransmitter activity, to several days or even weeks for effects mediated by neurotrophic signalling and changes in gene expression.

In the case of neurotransmitter effects, extracellular levels of 5-HIAA – a serotonin breakdown product reflecting the activity of the serotonergic system – remained elevated to approximately 180% of the baseline value for 1–4 hours following a single injection of Semax in rats [13]. This indicates a sustained neurochemical effect persisting for several hours following a single dose.

For neurotrophic effects – concerning BDNF and NGF, proteins that support the growth and survival of brain cells – the picture is more dynamic. Changes in BDNF gene activity appeared as early as 20 minutes after intranasal administration in rats, reached significant levels after 90 minutes, and returned close to baseline levels approximately 8 hours after administration in the hippocampus. The frontal cortex showed a slightly different temporal pattern [2].

However, the effects of BDNF do not end when BDNF levels return to baseline. BDNF works by activating its receptor – TrkB – which then triggers a cascade of intracellular signalling processes. These downstream signalling processes last much longer than the period of elevated BDNF levels themselves.

In patients post-ischaemic stroke treated with Semax, plasma BDNF levels remained elevated throughout the study observation period, suggesting that repeated dosing provides sustained neurotrophic elevation rather than a series of transient peaks [14]. Earlier Russian clinical literature has also reported that Semax effects on cognitive functions and resistance to hypoxic conditions in humans persisted for 20–24 hours after a single intranasal dose of 0.015–0.050 mg/kg [15]. This duration of action significantly exceeds what would be expected based on the pharmacokinetics of the intact molecule in the blood and reflects neurotrophic and genetic mechanisms that outlive direct peptide receptor interactions.

Does Semax accumulate in the body with regular use?

No published studies have directly investigated whether Semax accumulates in tissues or if its receptors become desensitised – meaning they become less responsive over time – with regular use. Based on available evidence, however, Semax does not appear to cause the progressive accumulation seen with many small-molecule drugs that are slowly eliminated.

As a peptide, Semax undergoes rapid enzymatic breakdown in biological fluids. This degradation profile makes its significant accumulation in tissues with regular use pharmacokinetically unlikely. In studies of chronic administration in rats over 10-14 days, persistent and progressive behavioural effects – including reduced anxiety and antidepressant-like activity – were observed, with no signs of tolerance or waning response over time. The authors attributed these sustained effects to progressive activation of the serotonergic system and a sustained increase in BDNF [16].

In clinical stroke trials, repeated administration of Semax over two ten-day treatment courses maintained elevated plasma BDNF levels throughout the observation period, consistent with sustained pharmacological engagement rather than receptor desensitisation or trophic depletion [14].

The formulation of Semax based on phospholipid nanoparticles – a delivery system that envelops the peptide with tiny fat molecules, protecting it from degradation – has also been investigated as a strategy to further prolong resistance to enzymatic degradation [17]. This approach could theoretically alter the pharmacokinetic profile by slowing down degradation and maintaining active Semax in tissues for a longer period. However, no clinical pharmacokinetic data regarding this formulation have been published to date.

Generally speaking, although a lack of formal studies on accumulation is a recognised limitation, available functional data do not suggest progressive accumulation or the development of tolerance with short-term regular administration.

Key limitations of Semax pharmacokinetic studies

Interpreting the available pharmacokinetic data for Semax, several significant limitations should be borne in mind.

Firstly, practically all direct pharmacokinetic measurements – including brain penetration rates, estimated half-lives, and metabolite identification – derive from rat studies using radiolabelled peptides. Direct translation of these findings to human pharmacokinetics is fraught with significant uncertainty as humans and rats can process compounds differently.

Secondly, no published pharmacokinetic studies in humans has measured levels of Semax in the blood over time under controlled conditions. This means that precise values for the half-life in humans, percentage of bioavailability, and volume of distribution – a measure of how widely a substance spreads throughout the body’s tissues – remain unknown.

Thirdly, because Semax breakdown products – HFPGP and PGP – retain their own biological activity, conventional pharmacokinetic assessments based solely on parent molecule concentrations significantly underestimate the actual biological duration of action. Measuring only Semax in the blood provides an incomplete picture of the true duration of pharmacological effects.

Fourthly, route-dependent differences in Semax effects suggest that its pharmacokinetic behaviour differs significantly between nasal, intraperitoneal, and subcutaneous administration. These differences have yet to be fully characterised in the published literature.

Future studies using modern analytical techniques – such as LC-MS/MS, a highly sensitive method for measuring specific molecules in biological fluids – conducted in humans via different routes of administration would significantly expand the scientific understanding of Semax's pharmacokinetics.

Disclaimer

This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim about the efficacy of Semax in treating any medical condition. Semax remains a research compound in most countries, including the United States and most European countries, and is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of human clinical trials. Additional well-designed clinical studies are necessary to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans. Anyone considering the use of any research peptides should consult with a qualified healthcare professional.

References

1. Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskiĭ, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055
2. Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
3. Lebedeva, I. S., Panikratova, Ya. R., Sokolov, O. Yu., Kupriyanov, D. A., Rumshiskaya, A. D., Kost, N. V., & Myasoedov, N. F. (2018). Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine, 165(5), 653–656. https://doi.org/10.1007/s10517-018-4234-3
4. Dolotov, O. V., Zolotarev, Yu. A., Dorokhova, E. M., Andreeva, L. A., Alfeeva, L. Yu., Grivennikov, I. A., & Miasoedov, N. F. (2004). The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Biochemical Chemistry, 30(3), 241–246. https://doi.org/10.1023/b:rubi.0000030127.46845.f0
5. Potaman, V. N., Alfeeva, L. Y., Kamensky, A. A., Levitzkaya, N. G., & Nezavibatko, V. N. (1991). N-terminal degradation of ACTH(4-10) and its synthetic analogue semax by rat blood enzymes. Biochemical and Biophysical Research Communications, 176(2), 741–746. https://doi.org/10.1016/s0006-291x(05)80247-5
6. Zolotarev, Yu. A., Dadaian, A. K., Dolotov, O. V., Kozik, V. S., Kost, N. V., Sokolov, O. Yu., Dorokhova, E. M., Meshavkin, V. K., Inozemtseva, L. S., Gabaeva, M. V., Andreeva, L. A., Alfeeva, L. Yu., Pavlov, T. S., Badmaeva, K. E., Badmaeva, S. E., Bakaeva, Z. V., Kopylova, G. N., Samonina, G. E., Vas’kovskiĭ, B. V., Grivennikov, I. A., Zozulia, A. A., & Miasoedov, N. F. (2006). Evenly tritium-labelled peptides and their in vivo and in vitro biodegradation. Bioorganic Chemistry, 32(2), 183–191. PMID: 16637290 https://pubmed.ncbi.nlm.nih.gov/16637290/
7. Shevchenko, K. V., V’iunova, T. V., Nagaev, I. Yu., Andreeva, L. A., & Miasoedov, N. F. (2013). Proteolysis of simple glyprolines by leucine aminopeptidase and enzymes from nasal slime, brain membranes, and rat blood. Bioorganic Chemistry, 39(3), 320–325. https://doi.org/10.1134/s1068162013030151
8. Shevchenko, K. V., V’iunova, T. V., Nagaev, I. Yu., Andreeva, L. A., Alfeeva, L. Yu., & Miasoedov, N. F. (2011). Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases. Russian Chemical Reviews, 37(4), 475–482. https://doi.org/10.1134/s1068162011040133
9. Magrì, A., Tabbì, G., Giuffrida, A., Pappalardo, G., Satriano, C., Naletova, I., Nicoletti, V. G., & Attanasio, F. (2016). Influence of the N-terminus acetylation of Semax, a synthetic analogue of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry, 164, 59–69. https://doi.org/10.1016/j.jinorgbio.2016.08.013
10. Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2017). Synacton and individual activity of synthetic and natural corticotropins. Journal of Molecular Recognition, 30(5). https://doi.org/10.1002/jmr.2597
11. Manchenko, D. M., Glazova, N. Yu., Levitskaia, N. G., Andreeva, L. A., Kamenskiĭ, A. A., & Miasoedov, N. F. (2010). Nootropic and analgesic effects of Semax following different routes of administration. I.M. Sechenov Russian Journal of Physiology, 96(10), 1014–1023. PMID: 21268834
12. Ashmarin, I. P., Samonina, G. E., Lyapina, L. A., Kamenskii, A. A., Levitskaya, N. G., Grivennikov, I. A., Dolotov, O. V., Andreeva, L. A., & Myasoedov, N. F. (2005). Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001
13. Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
14. Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischaemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
15. Ashmarin, I. P., Nezavibat’ko, V. V., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analogue 4-10-semax (15 years of its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
16. Vilenskiĭ, D. A., Levitskaia, N. G., Andreeva, L. A., Alfeeva, L. Yu., Kamenskiĭ, A. A., & Miasoedov, N. F. (2007). Effects of chronic Semax administration on exploratory activity and emotional reaction in white rats. Rossiyskiy Fiziologicheskiy Zhurnal imeni I.M. Sechenova, 93(6), 661–669. PMID: 17850024
17. Shevchenko, K. V., Khrapko, A. P., Schwets, V. I., & Myasoyedov, N. F. (2009). The use of phospholipid nanoparticles for increasing Semax resistance in various proteolytic biological media. Doklady Biological Sciences, 429, 505–507. https://doi.org/10.1134/s0012496609060076